Gilead Sciences: What to Make of Its Latest Failure?

On a day that’s seen the iShares Nasdaq Biotechnology ETF (IBB) rise, shares of Gilead Sciences (GILD) are falling after the biotech giant said a drug trial for the treatment of pancreatic cancer had failed. RBC’s Michael Yee and team say they’re “not surprised” by the result: Gilead reported a Phase II study in pancreatic [...]